Introduction Phyllanthus niruri is a traditional shrub of the genus Phyllanthaceae with long-standing Ayurvedic, Chinese and Malay ethnomedical records. Preliminary studies from cell and animal model have provided valuable scientific evidence for its use. Aim This review aims to summarize selected scientific evidence on the pharmacological properties of P. niruri over the past 35 years while identifying potential areas of further development of this herb as an economical adjunct. Methods The review covers literature pertaining to the evidence base therapeutic potential of P. niruri spanning from 1980 to 2015 available on PubMed.
Introduction
Phyllanthus niruri is a perennial tropical shrub, which has been used for a wide range of diseases in South and southeast Asian traditional medicine, including but not limited to jaundice, diarrhoea, dyspepsia, genitourinary infections and renal stones. In Brazil, where the plant is known as 'Chanca Piedra' or 'stone breaker', preparations of P. niruri are considered folk remedies for renal and vesicular calculi. [1] Traditional medicine systems, such as Ayurvedic and Unani medicine, have utilized the leaves and fruit, to treat gallstones and jaundice. In Malay traditional medicine, P. niruri, vernacularly known as 'dukong anak', is used for kidney disorders and cough. [2] In South India, where the herb is called Bhumyamalaki, the herb is believed to treat constipation, gonorrhoea and syphilis. [3] In northern India, this herb locally known as 'pitirishi' has gained a reputation as a household remedy for asthma, bronchitis and even tuberculosis. [4] The young shoots of this herb may at times be used as an infusion in cases of chronic dysentery. [5] Among traditional Chinese medicine circles, P. niruri or 'zhu zi cao' has traditionally been used to alleviate liver injury secondary to various hepatotoxic agents. In fact, ever since the landmark animal study by Venkateswaran and colleagues which demonstrated for the first time in vivo the potential anti-hepatitis B activity of P. niruri, [6] this herb has received significant scientific interest leading to a range of studies looking at the various therapeutic potential of this plant species.
Phytochemical studies on this plant, from as early as 1861 when Ottow first isolated the lignan phyllanthin from this plant, [7] to as recent as the isolation of potential anti-HBV phytochemicals nirtetralin and niranthin, [8, 9] have revealed that this plant is rich in tannins, flavonoids, alkaloids, terpenes, coumarins, lignans and phenylpropanoids, which are responsible for the pharmacological activity of P. niruri. Table 1 summarizes the various compounds that have been isolated from this herb used in research. Despite its wide range of uses from an ethnomedicinal point of view, research regarding most of these potential therapeutic applications has not reached the level of clinical trials. As a matter of fact, there is a lack of consolidation regarding the current state of knowledge pertaining to P. niruri research. Heterogeneity of primary studies on P. niruri has also precluded an objective assessment of the plants potential and the mechanisms for most of the therapeutic activity of this herb have yet to be defined. P. niruri may potentially be an important drug lead as it should be reiterated that natural products from herbs are still crucial sources of novel therapeutic agents and new chemical entities. In addition, the previous over-reliance on combinatorial chemistry and the fact that it does not necessarily yield vast and pharmacologically feasible libraries has re-emphasized the importance of exploring natural products. The exploration of these natural products may lead to the development of innovative natural product-like libraries, which when coupled with the introduction of high-throughput screening assays, would be able to provide new drug leads for further development. Harnessing the therapeutic potential of common, multipurpose herbs like P. niruri provides more accessible and economical drugs, which not only target a wide range of chronic diseases, but have fewer side effects compared with synthetic agents. To enable more targeted future research on this plant, consolidation of scientific evidence and possible gaps in the knowledge need to be addressed. The present review aims to summarize and consolidate the current state of scientific evidence available on PubMed from 1980 until 2015 on the pharmacological properties of P. niruri. It will identify areas of further development of this herb as an economical adjunct or even as a novel alternative therapeutic agent and provide a direction for future research in the development of new Phyllanthus-based drugs.
Antioxidant and hepatoprotective activity
The antioxidant hepatoprotective activity of P. niruri may be due to its rich content of flavonoids, tannins, lignans and terpenes, which possess antioxidative traits. One of the earliest in-vitro studies on the antioxidative hepatoprotective role of P. niruri demonstrated that hexane extract of P. niruri contained lignans such as phyllanthin and hypophyllanthin, which protected rat hepatocytes against carbon tetrachloride and galactosamine-induced hepatotoxicity.
[10] Several other studies have additionally proven the hepatoprotective effect of P. niruri in animal and cell culture models exemplified by the reduction in liver enzyme levels. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] It is, however, important to note that while such reduction in enzyme levels is observed, the exact mechanism for this reduction remains unknown. Additionally, the level and type of enzyme that have shown reduction appear to vary between studies suggesting that there may be multiple mechanism involved in the reduction of these liver enzyme levels. Methanolic extracts of P. niruri reduced the levels of TBARS (thiobarbituric reactive substances) in streptozotocin-induced diabetic rats besides improving the levels of reduced glutathione (GSH) and increasing the activity of endogenous antioxidants -superoxide dismutase (SOD) and catalase (CAT) in rat liver, kidneys, heart and brain tissues.
[28] Similar results were also replicated in a study involving IDDM and NIDDM rats administered with ethanolic extracts of P. niruri.
[29] When administered to diabetic Wistar rats, aqueous P. niruri extract not only normalized the activity of endogenous antioxidants and levels of plasma vitamin C and vitamin E, but also decreased malondialdehyde (MDA) lipid peroxidation rates.
[30] It can be surmised that P. niruri contains bioagents, which inhibit lipid peroxidation and prevent excessive superoxide synthesis secondary to chronic hyperglycaemia. Hence, P. niruri may alleviate lipoprotein metabolism abnormalities, reduce cholesterol-phospholipid ratios, control biomembrane damage and decrease ROS-linked lipid peroxidation. [28] [29] [30] P. niruri is also a potent NO-quenching agent. An Ayurvedic polyherbal formulation containing P. niruri had nitric oxide scavenging properties nearly 1.6 times greater than that of Gingko biloba preparations.
[18] The role of P. niruri as an anti-NO agent is significant since abnormal elevation of NO is responsible for the production of intermediate compounds, which are associated with genotoxicity. While aqueous extracts were more efficacious than methanolic preparations in normalizing ALT levels, more importantly, it was the protein fraction, which had greater hepatoprotectivity against tetrachloride poisoning.
[20] The fact that the hepatoprotective activity diminished after preadministration heating and upon addition of trypsin suggested that the hepatoprotective effect of P. niruri was due to its protein fractions. Subsequently, studies isolated a 35-kDa polypeptide chain, which displayed significant prophylactic and cytoprotective effects against tertiary butyl hydroperoxide (TBHP).
[31] It is a repetition of what was mentioned prior and therefore can be excluded. However, more comprehensive studies to elucidate the exact antioxidative mechanism of P. niruri proteins have yet to be executed.
Other studies on the in-vitro antioxidant properties of methanolic and aqueous preparations of P. niruri have shown that leaf and fruit extracts of P. niruri displayed significant inhibition of iron-overload microsomal lipid peroxidation and significant DPPH radical-scavenging activity. Aqueous extracts possessed more potent ROSquenching property than alcoholic extracts and even displayed DPPH and ABTS scavenging activities comparable with ascorbic acid.
[32] Another study showed that crude aqueous extracts of P. niruri leaves exerted dose-dependent inhibition of Fe(II)-induced lipid peroxidation, which may suggest its potential use for the treatment of brain and liver iron toxicity. [33] In addition, the iron-chelating property of aqueous extracts may provide a novel neuroprotective therapy for Fe(II)-associated oxidative stress in the brain, which is involved in the pathobiology of Alzheimer's disease. [34] P. niruri extracts also possess potential as prophylactic antioxidative agents. Rats pretreated with P. niruri before being administered carbon tetrachloride had lower hepatic malondialdehyde (lipid peroxidation product) levels. [22] Studies focusing on the in-vivo hepatoprotective activity of P. niruri against paracetamol-induced hepatotoxicity [15, 16] observed the normalization of liver enzyme profiles and non-enzymatic antioxidant levels via the decrease in ironinduced peroxidation of hepatocyte biomembranes. This is significant since paracetamol poisoning has limited and often ineffective treatment options, which depend heavily on N-acetyl cysteine.
[35] Studies on aspirin and iron hepatotoxicity have shown that ROS promote apoptosis by mediating ERK, [17] JNK [14] and p38 [14, 17] mitogen-activated protein kinase (MAPK) pathway activation. Therefore, the scavenging activity of P. niruri may interfere in ROS-induced apoptosis by inactivating these pathways. [13, 14, 17, 19, 23] However, no molecular studies focusing on this aspect have been executed. P. niruri may also prevent the progression of thioacetamide (TAA)-induced liver cirrhosis in rats by regulating the expression of transforming growth factor (TGFbeta), collagen alpha 1 (Collalpha1), matrix metalloproteinase-2 (MMP2) and tissue inhibitor of metalloproteinase-1 (TIMP 1) genes through its two constituents: 4-O-caffeoylquinic acid and quercetin 3-O-rhamnoside. [11, 12] This is the only study which has explicitly linked the antioxidant property of P. niruri with its epigenetic activity. Despite the preponderance of in-vitro and animal studies, there has only been one experiment on human subjects conducted concerning the antioxidant properties of P. niruri. This study investigated the plasmatic effect of P. niruri tea on healthy subjects [36] whereby it was observed that drinking P. niruri tea caused a transient rise in plasma ascorbic acid and a more sustained increase in plasmatic gallic acid within 24 hours. However, there was insignificant improvement in SOD and CAT activity, probably due to the short duration of tea intake. In general, this herb has been shown to significantly restore the reduced levels of GSH [13] [14] [15] 17, [23] [24] [25] and various antioxidant enzymes [15, 19, 20, [23] [24] [25] and lower lipid peroxidation. [13, 15, 17, 19, 20, [23] [24] [25] However, a study has shown that P. niruri may have adverse effects on the kidneys and testes.
[21]
Antidiabetic -hypoglycaemic action
Increased oxidative stress due to chronic hyperglycaemia is a widely accepted factor in the progression of diabetes and its complications. Animal studies using extracts of P. niruri have demonstrated dose-dependent improvements in fasting blood sugar, improved glucose tolerance and restoration of pancreatic tissue architecture, which may be due to inhibition of enzymatic pathways in intestinal carbohydrate digestion and glucose storage. [28, 37, 38, 39] It is thought that the bioactive agents of the extract possess insulinmimicking activity or potentially may stimulate the production of insulin as observed by the extracts ability to improve hepatic glycogen content and increase liver hexokinase activity.
[29] Despite these findings, the antidiabetic activity of Phyllanthus remains uncertain with varying results from different members of the genus. [40, 41] Review of existing studies suggest that the authors have used a variety of methods to induce diabetes, differing extraction method and dosages. This has invariably precluded the direct comparison of studies to ascertain the true functional properties of P. niruri as an antidiabetic agent although it has long been employed as a traditional treatment for alleviation of non-insulindependent diabetes.
[42]
Anti-inflammatory, antinociceptive and analgesic activity Studies on the anti-inflammatory, antinociceptive and analgesic activity of P. niruri have mainly revolved around animal models. Intraperitoneally administered methanol extract of dried callus tissue of P. niruri caused antinociceptive effects on five different models of pain, suggesting that P. niruri possessed analgesic properties. However, the mechanism of action is still debated on. Currently, there are still no molecular studies on the effect of P. niruri extracts on pain pathways. Obidike et al. [43] deduced that the anti-inflammatory and antinociceptive action of P. niruri was mediated via the peripheral nervous system. In his study on rats, whole plant chloroform extract was found to inhibit writhing response, reduce yeast-induced pyrexia, alleviate albumin-induced inflammation with an effect comparable to aspirin, increase pain threshold in the Randall-Selitto test but not the hot plate test for thermally induced nociception. Hence, Obidike deduced that P. niruri chloroform extract exerted antipyretic, antiinflammatory and antinociceptive effects ". . .. . . the peripheral nervous system rather than the central nervous system." However, other rat studies suggest that the hydroalcoholic [44] [45] [46] [47] and spray-dried standardized [48, 49] extracts may exert both significant peripheral and central analgesia. Hence, there remains a need for the further study of the effect of P. niruri extracts on major pain pathways to clarify the ambiguity that surrounds its analgesic mechanism. In an attempt to identify the specific analgesic and antiinflammatory bioactive agents, two studies have shown that only spray-dried extract of leaves possessed analgesic antiallodynic and anti-edematogenic and that these appeared to be a function of gallic acid concentration. [49, 50] In addition, corilagin, which is found in abundance in P. niruri extracts, has also been identified as an antihyperalgesic tannin, which derives its activity from its involvement in the glutamatergic system.
[50] Corilagin was found to reduce acetic acid writhing response in a dose-dependent manner and also displayed significant neurogenic analgesia, suggesting the possibility that corilagin either attenuates the release of inflammatory endogenous mediators in the peripheral circulation or induces analgesia via the direct interaction with peripheral nociceptors or bradykinins. [51, 52] Moreover, the antihyperalgesic activity of corilagin may be due to its inhibition of the glutamatergic system via the possible prevention of NO synthesis by corilagin. This is also in accordance with the outcomes of a study by Martini et al. [53] Hypolipidaemic activity Studies pertaining to the lipid-lowering activity of P. niruri have all been conducted using rat models. It is interesting to note that no studies using rabbit models have been performed despite that fact that it is widely accepted that rabbits are more reliable hyperlipidaemic models. Additionally, no in-depth in-vitro or molecular studies have been conducted to date to elucidate the exact mechanism involves in the activity of lowering lipid levels. However, animal studies provide strong evidence that P. niruri possesses antioxidant-linked hypolipidaemic properties.
[29,30,37, [54] [55] [56] Of interest is the role of P. niruri in redox changes, disruption of lipoprotein export associated with alcoholic liver disease and lipid peroxidation secondary to alcohol-induced oxidative stress. [57, 58] However, there is a need for comparative studies to examine the hypolipidaemic capacities of different types of P. niruri extracts, since there has yet to be uniformity between the studies concerning the type of extract used, with one using ethanolic extracts, [56] one methanolic extract, [37] three aqueous [29, 30, 55] and one unstated, [54] apart from the discrepancies in concentrations of decoctions used in these studies. Furthermore, animal studies on mammals other than rats are needed before one considers clinical trials, as the pathobiology associated with rodent Triton-induced hyperlipidaemia may differ from human pathology. In addition, phytochemical screening plays a key role in narrowing down the range of phytochemicals likely to be responsible for P. niruri hypolipidaemic activity.
In a study on Triton-and cholesterol-induced hyperlipidaemic rats, P. niruri lowered the major serum lipid biomarkers significantly, [54] corroborating the results of a previous animal study [56] where administration of alcoholic extracts of P. niruri lowered the low-density lipoprotein levels. Hyperlipidaemic rats orally administered P. niruri experienced reduced serum levels of lipidaemic parameters such as total cholesterol, triglycerides, low-density lipoprotein, apo-LDL and VLDL-TG while partially reactivating plasma lecithin: cholesterol acyltransferase(LCAT) and postheparin lipolytic activity. It also restored hepatic lipoprotein lipase activity, normalized cholesterol biosynthesis and increased receptor-mediated LDL catabolism. Faecal excretion of cholic and deoxycholic acids was also normalized. The high-density lipoprotein and apo-HDL levels also recovered when rats were fed P. niruri extract, which could be linked to improved LCAT activity. It is thought that the LDL-lowering property of P. niruri may also be due to the increased binding of b-lipoproteins with hepatic LDL receptors. [59] The increased faecal excretion of bile acids may be due to the flavonoids present in P. niruri, as studies have proven that rats given phenolic flavonoids experience similar results due to increased lipid catabolism and reduced reabsorption of bile acids and cholesterol from the gut. [60, 61] In general, these studies demonstrated dose-dependent hypolipidaemic activity of P. niruri extracts, with a study showing that P. niruri may possess greater hypolipidaemic activity than glibenclamide.
[37] There was, however, in one study, a degree of weight gain observed in the rats administered the P. niruri extract, which is similar to the side effects of thiazolidinediones.
[37] As such, more studies are required to study the potential adverse effects of P. niruri as an antidiabetic agent especially when treating obese patients in need of urgent blood glucose and weight control. It is also evident that the hypolipidaemic action of P. niruri and its potential use among patients suffering from alcoholic liver disease is closely linked with its lipid peroxidation-quenching action, which may be a function of its high polyphenolic content. [29, 55] Cardioprotective activity
Only one major animal study has been conducted to investigate the attenuating action of P. niruri extracts in preventing doxorubicin-associated cardiotoxicity. Pretreatment of rats with P. niruri extract significantly protected rat myocardia from doxorubicin toxicity by normalizing cardiac biomarkers, restoring intracellular levels of enzymatic and non-enzymatic antioxidants and decreasing rat cardiac tissue peroxidation. [62] Antiplatelet and vasorelaxant activity Methyl brevifolin carboxylate isolated from P. niruri exerted vasorelaxant effect on rat aortic rings via inhibition of noradrenaline-induced vasocontraction mediated by a decrease in calcium ion influx through receptor-operated Ca 2+ channels. [63] The same compound also acted as a platelet aggregation inhibitor. [64] Wound healing and anti-ulcer properties A rat study involving the oral administration of ethanolic extracts of the herb showed significant inhibition of the development of indomethacin-induced ulcers. The antiulcer activity has been attributed to gallic acid, beta-sitosterol, ellagic acid and alkaloids-4-methoxy-securinine. [65] Extracts of P. niruri also protect against ethanol-induced gastric mucosal ulceration in rats [66] and reverse dexamethasone-suppressed burn wound healing. [67] The exact mechanisms have not been elicited to date.
Antiviral activity
Perhaps the most prominent among the potential therapeutic effects of P. niruri is its antiviral activity. Studies conducted on sera obtained from chronic hepatitis B patients and woodchuck hepatitis (WHV)-infected woodchucks, which were treated with P. niruri extracts, showed decreased viral antigen levels. [68] Overall, aqueous extracts of P. niruri have been shown to possess significant antiviral potential and appear promising especially with regard to hepatitis B carriers. [6] Clinical studies on hepatitis B patients showed that 50-60 per cent of patients who were administered P. niruri extract experienced HBsAg seroconversion. The reduction in HBsAg antigen may have been due to the inhibitory effect of P. niruri on hepatitis B viral genetic replication. [69, 70] Of note, in a study where patients were treated with extracts of three different members of the genus Phyllanthus, it was observed that extracts of P. niruri were more likely to induce reductions in HBeAg titres. [71] Although not all the bioagents responsible for the antihepatitis B activity of P. niruri have been identified, molecular studies have determined the molecular structure of a novel lignin found in P. niruri, nirtetralin B and its two stereoisomers, nirtetralin and nirtetralin A. Nirtetralin significantly inhibited HBsAg and HBeAg levels in vitro. [72] All three lignans had a dose-dependent inhibitory effect on the in-vitro titres of HBV antigens. Moreover, inhibition ratios for nirtetralin and nirtetralin B were significant when compared with acyclovir, suggesting that these compounds were promising as novel anti-HBV antivirals. In general, lignans had low cytotoxicity on host cells, suggesting that these compounds could safely be given at non-toxic dosages without incurring undesirable adverse drug reactions. [73, 74] To date, no systematic review has been conducted on the anti-hepatitis B activity of P. niruri per se. However, there have been a number of reviews since the year 2000, on the utility of members of the Phyllanthus genus as potential antiviral agents for chronic hepatitis B infection. [75] [76] [77] One review concluded that Phyllanthus extracts were as effective as interferon in the terms of HBsAg seroconversion. Moreover, the extracts of members of the Phyllanthus genus were more effective than other herbal preparations in eliminating hepatitis B surface antigen from patient sera and in normalizing other hepatic parameters. Phyllanthus extracts also worked more effectively when used in combination with interferon. Although the above conclusions were not based on a single species of Phyllanthus in particular, the overall findings of this review were suggestive of the antiviral potential of the genus Phyllanthus, and by extrapolation, P. niruri. However, this review also reported that the evidence presented was still insufficient to confirm whether Phyllanthus extracts had clinically significant benefits given that most of the 22 studies analysed were rather heterogenous in terms of methodology, with a prevailing lack of consensus regarding the species of Phyllanthus tested and clinically relevant experimental parameters. [75] Subsequent reviews have concluded that while there is insufficient evidence to suggest that the extracts of Phyllanthus are, by themselves, comparable in efficacy to current antiviral agents, and hence justify their use in chronic hepatitis B patients, such extracts may enhance the potency of an antiviral agent if used in combination. [76, 77] Despite these evidences, to justify the use of Phyllanthus for chronic hepatitis B patients, there is a need for more high-powered studies to assess the effectiveness of Phyllanthus against current antiviral therapy. Additionally, it may be particularly important for investigator to assess the quality of existing preclinical research in terms of their scientific rigour and reproducibility.
The antiviral activity of P. niruri is not just limited to hepatitis B. Aqueous extracts of P. niruri containing repandusinic acid, a hydrolysable tannin, have been shown to exert a significant inhibitory effect on HIV-1 reverse transcriptase (HIV-1-RT). [78] Kinetic analysis suggests that repandusinic acid competitively inhibits the template primer during the process of reverse transcription. However, repandusinic acid does not bind to the same site as dTTP analogues such as AZT (azidothymidine). Despite the promising results with respect to the inhibition of HIV-1-RT activity, repandusinic acid seemed to exert less significant inhibition of DNA pol alpha. [78] With regard to the resultant degree of cytopathogenicity, repandusinic acid reduced the amount of pathogenic changes in HIVinfected MT4 cells, and the results even suggested that repandusinic acid may be more potent than AZT in inhibiting HIV cytopathogenicity. Moreover, azidothymidine and repandusinic acid may work in synergy when administered as a combination. However, the action of repandusinic acid has only been studied at the cellular level, and no animal or human studies on the anti-HIV therapeutic effects of repandusinic acid have been carried out. The study by Ogata et al. was a milestone in itself as it highlighted that hydrolysable tannins were important potential antiviral agents in HIV therapeutics. While it was previously known that phenols, flavonoids and alkaloids were major chemical constituents of P. niruri extracts and had great potential as antiviral agents, this study highlighted hydrolysable tannins such as repandusinic acid, as another novel HIV-1-RT inhibitor. In addition, although it was previously believed that tannins generally fared poorly on the therapeutic index and, due to their lack of specificity, could interfere in macromolecular interactions, repandusinic acid clearly demonstrated high specificity for HIV-1-RT, hence implying that it may have less crossinteractions with other macromolecules than previously believed. [78] This significant toxic selectivity for virusinfected cells was replicated in a subsequent study on alkaloidal extracts of P. niruri, [79] with a greater preference for HIV-2-infected cell lines. Like repandusinic acid, the alkaloid extract of P. niruri was also found to have an inhibitory effect on HIV-1 replication and dose-dependent cytoprotectivity against HIV infection. A separate study on a cohort of ten HIV patients who were administered the extracts of five different traditional herbs (with P. niruri being one of them) for at least half a year resulted in 7 of the 10 patients experiencing a rise in CD4 count. Despite this significant finding, no follow-up studies have been conducted on the mechanisms of action underlying these clinical findings.
Apart from repandusinic acid, there are other P. niruri phytochemicals, which may form new classes of anti-HIV agents. Qian-Cutrone and colleagues isolated a glucopyranoside, niruriside, which was found to inhibit REV/RRE binding during the movement of viral RNA from the cell nucleus to the cytoplasm. However, despite being found to be a specific REV/RRE inhibitor, niruriside did not display satisfactory levels of cellular protection in cases of acute HIV-1 infection. [80] A study exploring the antidengue activity of members of the genus Phyllanthus showed that Phyllanthus extracts worked best when administered simultaneously with DENV-2 inoculum implying that the Phyllanthus extract most probably affected the early phases of viral infection such as the viral attachment and entry. [81] Proteome analysis showed that the expression of 13 host and viral proteins involved in viral entry and replication, molecular chaperoning, cytoskeletal assembly and cellular metabolisms was altered, including calreticulin, Trim 1, heat-shock 70-kDA protein, beta-actin, DNA topoisomerase I, NS3, G3PD (glyceraldehyde-3-phosphate dehydrogenase), RBM1 (RNA-binding motif 1), DNA mismatch repair protein Msh2, dengue virus NS2bNS3 and polysialyltransferase. [81] Apart from that, P. niruri-synthesized silver nanoparticles demonstrated significant larvicidal, pupicidal and adulticidal activity against Aedes aegypti both in laboratory and field settings. [82] Antibacterial activity
With the increase in antibiotic resistance rates and the need for novel antibiotics, which have optimal antimicrobial activity with minimal toxicity, there is renewed interest in exploring phytochemicals from everyday plants. A possible reason for the increased interest in extracting phytochemicals for the development of novel antibiotics is the threat of plant species extinction, hence inciting a need to explore the medicinal potential of these resources before they are lost. [83] P. niruri contains various phytochemicals, which exert antimicrobial and antiprotozoal properties. [84] These include rutin, [4, 85] gallocatechin, [86] prenylated flavanone glycosides, [87] quercetin, [88] quercitrin, [89] p-Cymene, [90] corilagin, [91] diosgenin, [92] securinine [93] and b-glucogallin. [94] Overall, studies on the antimicrobial activity of P. niruri extracts are still limited to in-vitro models and have not advanced to animal studies as of the time of writing.
[32, [95] [96] [97] [98] [99] [100] [101] These studies utilize different types of P. niruri extracts, with one study a comparison of methanolic, ethanolic and aqueous extracts, recognizing that different preparations yielded different compositions of pharmacophores. [101] To date, there are no studies known to specifically elicit the exact mechanism of action for the antimicrobial activity of the extracts. Of the 8 studies conducted to date concerning the antimicrobial potential of P. niruri, only four have carried out phytochemical screening of the extracts used. [97, 98, 100, 101] An agar well diffusion study conducted on the antimicrobial activity of aqueous and ethanolic extracts of the leaves and roots of 4 Indian herbs, including P. niruri, showed that the ethanolic extract was more effective against Escherichia coli and Staphylococcus aureus, whereas the aqueous preparation had greater activity against Proteus vulgaris and Bacillus subtilis but poor anticoliform activity. [95] It was observed that methanol extracts of P. niruri were twice as strong as that of aqueous preparations, with an MIC of approximately one-third that of aqueous extracts. In addition, both aqueous and methanolic extracts of P. niruri demonstrated significant activity against Listeria monocytogenes, the bacteria responsible for listeriosis, suggesting the potential of P. niruri as a food preservative. [96] A subsequent disc diffusion study found that both ethanolic and aqueous extract of P. niruri failed to inhibit the growth of the Gram-negative bacilli but demonstrated statistically more significant inhibitory activity against Gram-positive bacteria.
[32] The apparent difference in results between this study and that of Cheah and colleagues in 2011, [96] could be due to the use of varying solvents. This could suggest that the aqueous extracts contained a higher content of phenolic compounds compared with the ethanolic extract. [102] Agar diffusion assays in a study on Helicobacter pylori and three species of probiotic Lactobacilli revealed that P. niruri inhibited H. pylori in a dose-dependent manner while it did not affect the growth of lactic acid bacteria.
[97] The addition of proline to H. pylori agar did not reverse the inhibiting activity of P. niruri aqueous extract, suggesting that the anti-H. pylori property of P. niruri did not involve the inhibition of proline dehydrogenase, a membrane-associated protein linked with prokaryotic energy production. [103] The anti-H. pylori activity recorded in this study could be due to ellagitannins such as geraniin and corilagin contained in the aqueous extract, which have also been previously shown to act in a concentration-dependent manner against various antibiotic-resistant H. pylori strains [104] by rapidly precipitating agglutination of H. pylori cells. [105] The lack of activity against lactobacilli implies that the ellagitannins-rich aqueous extract was selective for the targeted pathogen (E. coli) instead of probiotic organisms. In terms of its anticoliform activity, methanolic extracts of P. niruri followed by its seeds, displayed greatest inhibition of E. coli activity. Overall, root extracts displayed the weakest antibacterial activity. [98] The optimal bacteriostatic action against E. coli, S. viridans, S. aureus and P. aeruginosa observed with methanolic leaf extract could be due to the action of flavonoids.
Methanolic extracts of P. niruri leaves acted directly on the cell wall in a concentration-dependent trend. There is a possibility that certain morphological or molecular features of Gram-positive cell walls are targets of the active agents of P. niruri methanolic extracts. [102] These binding sites have yet to be identified.
In short, different parts of the herb and the usage of different solvents could yield extracts with differing compositions of pharmacophores, hence affecting the antimicrobial spectrum of activity of this plant.
There is a need for more molecular studies to elicit exact mechanism for bioactive agents before we can proceed to animal studies. In general, methanolic extracts are more potent against Gram-positive microbes, followed by aqueous extracts and ethanolic extracts. The antibacterial activity of P. niruri is also dose dependent. However, the compatibility of methanolic extracts to the mammalian subject may need to be investigated using animal models, as methanol, a polar organic solvent, may be disruptive of cellular phospholipid membranes. Although there is noticeably poor Gram-negative activity, there is still a need for large-scale molecular studies to investigate the relationship between the morphology of Gram-negative bacteria and the lack of Gram-negative activity in P. niruri extracts.
Antiplasmodial and nematicidal properties
In-vivo [106] [107] [108] and in-vitro [109] [110] [111] [112] studies show that P. niruri extracts display antiplasmodial properties. This may be due to the terpene-rich content of P. niruri extracts. [111] Of interest, methanolic extracts displayed chemosuppressive action comparable with chloroquine and demonstrated better prophylactic activity than pyrimethamine. [108] Of note, a study on the nematicidal activity of P. niruri against Meloidogyne incognita and Rotylenchulus reniformis identified two prenylated flavanones as being responsible for the nematicidal activity of P. niruri. [113] Anti-urolithiatic activity A study on the effect of P. niruri extract on calcium oxalate (CaOx) crystallization in vitro showed that P. niruri restricted CaOx crystal growth and aggregation, showing its potential to disrupt the early stages of stone formation. [114] P. niruri also changed the shape of calculus in rats into a smoother and possibly more fragile form which could ease removal or dissolution of calculi. [115] A clinical study showed that P. niruri lowers urinary calcium in hypercalciuric patients subset among 69 calcium stone-forming patients. [116] Another clinical study demonstrated that in postextracorporeal shock wave lithotripsy patients who underwent therapy with Uriston, a P. niruri extract had higher stone-free rates than the control group. [117] Antihyperuricaemic activity Lignans from P. niruri were found to be antihyperuricaemic in animals; the effects were comparable with drugs for treating hyperuricaemia and gout-like allopurinol and probenecid. [118] A later study showed that the antihyperuricaemic property of the lignans was due to their uricosuric action. This study also showed that P. niruri methanol extract had antihyperuricaemic effect primarily attributed to its uricosuric action and partly via xanthine oxidase inhibition. [119] Antineoplastic activity Spray-dried extract of P. niruri (SDEPN) was found to be selectively toxic against various cancer cell lines -colorectal carcinoma (HT29) [120] cells, human hepatocellular carcinoma (HepG2), [120, 121] Huh-7 cells [121] and ovarian cancer cell lines SKOv3ip and Hey [122] -in addition to reduction in tumour incidence, tumour yield and tumour burden in mice. [123] Spasmolytic activity Alkaloid extracts of P. niruri demonstrated smooth muscle relaxation in urinary and biliary tracts. [124] Extracts of P. niruri leaves, stems and roots showed antispasmodic properties on several smooth muscles in vivo such as guinea pig ileum, rat uterus and canine vascular smooth muscles. Ether extracts were found to be most effective as antispasmodics. [125, 126] Immunomodulatory activity Extracts of P. niruri have proven to be potent murine lymphocytes mitogens and are able to induce surface activation maker (CD69), B and T lymphocyte proliferation. The production of interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) by P. niruri extract-stimulated naive splenocyte cultures was also increased in a concentration-dependent manner. Various indices of activation and functions of murine bone marrow-derived macrophages, such as phagocytosis, lysosomal enzymes activity and TNF-alpha release, were significantly enhanced by pretreatment with P. niruri extract, which also modulated macrophage nitric oxide release. [127] P. niruri also increased the expression of major histocompatibility complex-II and markers for dendritic cell maturation (CD40), activation (CD83) and costimulation (CD86) in a concentration-dependent manner. In a transgenic T-cell activation model, P. niruri-treated dendritic cells also presented Ova antigen to Ova-specific CD8(+) T cells more efficiently. [128] Anti-amnesic property
Isocorilagin from P. niruri has been shown to be two to three times more potent than galanthamine, the clinically used AChE inhibitor. Kinetic analyses suggested that isocorilagin is a non-competitive inhibitor for AChE. In-silico molecular docking revealed that isocorilagin effectively blocks substrate entry by forming hydrogen bonding with residues at the entrance of the AChE active site. [129] Discussion and Conclusion
The present review provides a comprehensive overview of selected scientific studies using the plant P. niruri. The plants' extensive use in traditional and complementary medicine for variety of diseased condition has led to a significant amount of scientific studies particularly using animal models. The present review demonstrates that P. niruri extracts have pharmacological potential in a large range of conditions as summarized in Appendix 1. Of the conditions investigated, it appears that P. niruri has commonly been investigated for its antiviral, hepatoprotective, hypolipidaemic and antibacterial activity. The positive findings seen in the articles reviewed here is likely due to the fact that there may be multiple bioactive compounds within crude extracts used in these studies. It is widely accepted that crude extracts are made up of a range of bioactive compounds and each compound may exert differing activity on body tissues. Nonetheless, only a handful of studies assessed the pharmacological potential of these bioactive compounds as most studies described the activity of methanolic and aqueous crude extracts. Therapeutic findings using crude extracts have limited translational value as investigators are unable to determine whether the findings are related to the action of a single bioactive compound or that of synergy between multiple bioactive compounds. This additionally relates to the extraction process used when preparing crude extracts. It is widely known that different extraction methods and use of solvents with different polarity yield different bioactive compounds and as such limits our ability to compare findings between studies. In performing our review, we observed that there was significant heterogeneity in study protocols and in some instances conflicting results, which suggest that some studies may not provide reproducible data. Additionally, the lack of information in some studies prevents our ability to replicate these studies to make an independent assessment of the therapeutic potential of the plant. When assessing pharmacological potential of novel therapeutic agents, it is essential that authors provide a comprehensive account of the experimental design and protocol and ensure proper standardization of material and techniques, an aspect that appears to be lacking in some studies in this review. Thus while the overall findings suggest an abundance of therapeutic potential of P. niruri, such findings must be interpreted with caution. There are still many aspects of research on this herb that need to be considered such as larger sample sizes, toxicological studies, mechanism studies and molecular analyses. Current evidence is largely limited to correlation between identified phytochemicals and their biological activities. There is a lack of mechanisms of action studies to understand the interaction of bioactive phytochemicals from P. niruri and their respective molecular targets. Essentially, more robust scientific methodologies are necessary before confirmatory decisions can be made on the potential of P. niruri. A key step before clinical trials may be considered.
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